T. Rowe Price Associates, Inc. 13D and 13G filings for Nurix Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 10:03 am Sale |
2023-12-31 | 13G | Nurix Therapeutics, Inc. NRIX |
T. Rowe Price Associates, Inc. | 2,391,866 4.900% |
-861,870 (-26.49%) |
Filing |
| 2023-02-14 12:38 pm Sale |
2022-12-31 | 13G | Nurix Therapeutics, Inc. NRIX |
T. Rowe Price Associates, Inc. | 3,253,736 6.900% |
-1,617,348 (-33.20%) |
Filing |
| 2022-02-14 2:35 pm Purchase |
2021-12-31 | 13G | Nurix Therapeutics, Inc. NRIX |
T. Rowe Price Associates, Inc. | 4,871,084 10.900% |
244,189 (+5.28%) |
Filing |
| 2021-08-10 1:41 pm Purchase |
2021-07-31 | 13G | Nurix Therapeutics, Inc. NRIX |
T. Rowe Price Associates, Inc. | 4,626,895 10.400% |
4,626,895 (New Position) |
Filing |